Industry Overview

India myocardial infarction market was valued at $457.7 million in 2025 and is projected to reach $1,066.0 million by 2035, growing at a CAGR of 8.9% during 2026–2035. The market growth is driven by the rising prevalence of cardiovascular diseases, increasing adoption of interventional cardiology procedures, and expanding healthcare infrastructure across India. According to the World Health Organization, cardiovascular diseases account for nearly 27% of total deaths in India, with heart attacks being a major contributor. Additionally, the growing burden of diabetes and hypertension is increasing the risk of myocardial infarction across younger populations. The demand for Percutaneous Coronary Intervention (PCI) procedures and advanced cardiac devices such as drug-eluting stents is rising significantly due to improved healthcare accessibility under government initiatives like Ayushman Bharat. Major end-users include private hospitals, public hospitals, and cardiac specialty centers, which are increasingly investing in advanced cath lab infrastructure and minimally invasive technologies.

Market Dynamics

Rising Cardiovascular Disease Burden Driving Market Growth

The increasing incidence of cardiovascular diseases is a key driver for the India myocardial infarction market. According to the World Health Organization, cardiovascular diseases are the leading cause of mortality globally, accounting for 17.9 million deaths annually, with a significant share originating from low- and middle-income countries like India. Rapid urbanization, sedentary lifestyles, and dietary changes have significantly increased the prevalence of coronary artery disease, directly contributing to myocardial infarction cases.

Government initiatives such as Ayushman Bharat have expanded access to cardiac procedures, increasing the number of PCI and CABG treatments in public healthcare institutions. Additionally, companies are focusing on product innovation and localization strategies (2025–2026), including expansion of stent manufacturing and cardiovascular drug portfolios to cater to cost-sensitive markets. Increasing awareness regarding early diagnosis and preventive care is further boosting demand for pharmacological treatments and monitoring devices.

High Treatment Costs and Pricing Regulations Limiting Growth

Despite strong growth potential, the market faces challenges due to pricing pressures and cost constraints. The Indian government has imposed price caps on coronary stents, which has reduced profit margins for manufacturers and impacted innovation investments. Additionally, advanced cardiac procedures such as PCI and CABG remain expensive for a significant portion of the population, especially in rural areas.

Supply chain disruptions and dependency on imported medical devices also pose challenges for manufacturers. Although local manufacturing initiatives are increasing, achieving cost efficiency and technological parity remains a hurdle. Companies are responding by investing in local production facilities, strategic partnerships, and cost-effective product innovations to maintain competitiveness while complying with regulatory frameworks.

Market Segmentation

• Based on the treatment type, the market is segmented into pharmacological treatment, interventional procedures, adjunct & supportive care.
• Based on the medical device type, the market is segmented into left ventricular assist device, pacemaker, catheters, implantable cardioverter defibrillator, and others.
• Based on the end-user, the market is segmented into public hospitals, private hospitals, cardiac specialty centers, and ambulatory surgical centers.

Pharmacological Treatment Segment Leads the Market

Pharmacological treatment dominates the India myocardial infarction market due to its widespread use in both acute and long-term management of heart attack patients. Drugs such as antiplatelets, anticoagulants, and statins are extensively prescribed across hospitals and outpatient settings. High patient volume and affordability of generic drugs in India further strengthen this segment. Between 2022–2026, pharmaceutical companies have expanded their cardiovascular drug portfolios and focused on increasing accessibility through partnerships and distribution network expansion. The dominance of this segment is also supported by the need for lifelong therapy in MI patients, ensuring consistent demand

Minimally Invasive Interventions Leading Revenue Momentum

Interventional procedures, particularly percutaneous coronary intervention (PCI), continue to represent the largest revenue contributor due to their direct linkage with high-cost hospital procedures and device utilization. Procedure volumes in India have shown steady expansion, with hundreds of thousands of interventions performed annually and consistent double-digit growth trends driven by rising coronary disease burden.  Adoption of stent-based therapy has accelerated as it offers faster recovery compared to bypass surgery, strengthening its clinical preference.
Key players such as Abbott Laboratories, Medtronic, and Boston Scientific are expanding portfolios with next-generation drug-eluting technologies. Recent developments highlight price regulation and inclusion in essential medicine lists, which have improved affordability and expanded patient access, further boosting procedural volumes.

Competitive Landscape

The India myocardial infarction market is highly competitive, with a mix of global pharmaceutical and medical device companies focusing on innovation, affordability, and distribution expansion. Companies such as Pfizer Inc., AstraZeneca plc, Novartis AG, Bayer AG, and Johnson & Johnson are actively investing in cardiovascular drug development and interventional technologies. These players are strengthening their market position through product innovation, partnerships, and geographic expansion while focusing on cost-effective solutions for emerging markets like India.

Recent Developments

• In September 2025, Meril Life Sciences introduced the Mizzo Endo 4000 robotic surgical system, marking a significant advancement in India’s minimally invasive and precision surgery capabilities. The platform integrates AI-driven 3D anatomical mapping, advanced visualization, and 5G-enabled telesurgery, enabling real-time remote procedures and expanding access to specialized care in underserved regions.

• In June 2025, Meril Life Sciences launched the MyClip TEER system, India’s first transcatheter edge-to-edge repair solution for severe mitral regurgitation, particularly in high-risk patients including those with post-myocardial infarction complications.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global India myocardial infarction market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.